Jupiter Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Jupiter Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,300	Closed	-$221K	–	594
2022 Q1	$221K	Sell	23,300 -24,735	-51%	-$232K	﹤0.01%	496
2021 Q4	$561K	Hold	48,035	–	–	0.01%	464
2021 Q3	$459K	Buy	+48,035	New	+$491K	0.01%	482
2021 Q1	–	Sell	-16,513	Closed	-$381K	–	591
2020 Q4	$381K	Buy	+16,513	New	+$338K	﹤0.01%	534

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jupiter Asset Management's FOLD Position: Q2 2022 in Review

Jupiter Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2022, closing a stake of 23,300 shares — an estimated $221K sold.

Jupiter Asset Management first reported a position in FOLD in Q4 2020 and held it in 4 quarters. The position peaked at $561K in Q4 2021. 212 funds tracked by Wall St. Rank hold FOLD as of Q2 2022.

Jupiter Asset Management reported no remaining Amicus Therapeutics position as of Q2 2022 after selling out during the quarter.
Jupiter Asset Management sold 23,300 Amicus Therapeutics shares in Q2 2022, an estimated $221K.
Jupiter Asset Management first reported a position in Amicus Therapeutics in Q4 2020 and held it in 4 quarters.
Jupiter Asset Management's Amicus Therapeutics position peaked at $561K in Q4 2021.
212 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2022.

Based on Jupiter Asset Management's 13F filing for Q2 2022, filed 10 Aug 2022.